What is the risk of meningioma associated with Depo‑Provera (medroxyprogesterone acetate) use in a reproductive‑age woman without a prior history of central nervous system tumors?

Depo-Provera (DMPA) is Associated with an Increased Risk of Meningioma, Particularly with Prolonged Use

Women using Depo-Provera (depot medroxyprogesterone acetate/DMPA) have an approximately 2.5-fold increased risk of developing meningioma, with the risk rising substantially after 4 years of continuous use or when started after age 31. However, the absolute risk remains low, with a number needed to harm of approximately 1,152 patients 1.

Understanding the Risk Profile

The most recent and highest-quality evidence from a 2025 US national database study demonstrates a relative risk of 2.43 (95% CI 1.77-3.33) for meningioma diagnosis in DMPA users compared to non-users 1. This risk is specifically confined to two high-risk scenarios:

• Duration >4 years of exposure
• Starting DMPA at age >31 years

A 2024 French national case-control study corroborates these findings, showing an odds ratio of 5.55 (95% CI 2.27-13.56) for injectable medroxyprogesterone acetate, with the excess risk driven by prolonged use (≥1 year) 2. Multiple meta-analyses confirm pooled odds ratios ranging from 2.68 to 3.49 for DMPA-associated meningioma 3, 4.

Clinical Characteristics of DMPA-Associated Meningiomas

These tumors have distinct features that inform clinical management:

• Predominantly WHO grade 1 (benign) with low chromosomal instability 5
• Multiple meningiomas are common (9 of 10 patients in one genomic study) 5
• Anterior and central skull base predilection 5
• Enriched for TRAF7 mutations, not NF2 mutations 5
• Potential for regression or stabilization after DMPA cessation 5, 6

FDA Recognition and Labeling

The FDA drug label for Depo-Provera explicitly warns: "Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long term use. Monitor patients on Depo-Provera CI for signs and symptoms of meningioma. Discontinue Depo-Provera CI if a meningioma is diagnosed" 7.

Practical Clinical Algorithm

Before Prescribing DMPA:

1. Screen for meningioma history - absolute contraindication if present
2. Assess age - heightened caution if >31 years
3. Discuss meningioma risk during contraceptive counseling, particularly for anticipated long-term use
4. Document informed consent regarding this specific risk

During DMPA Use:

• Monitor for neurological symptoms: headaches (especially new-onset or changing pattern), vision changes, seizures, focal neurological deficits
• Consider limiting duration to <4 years when alternative contraceptives are acceptable
• Reassess contraceptive choice at each injection visit, particularly approaching 4 years of use

If Meningioma Diagnosed:

1. Immediately discontinue DMPA 7, 6
2. Obtain baseline MRI for tumor characterization
3. Repeat MRI in 3-6 months to assess for regression or stabilization 6
4. Refer to neurosurgery/neuro-oncology for management decisions
5. Transition to alternative contraception - levonorgestrel IUD shows no increased meningioma risk 2

Comparison with Other Contraceptive Options

Importantly, no increased meningioma risk was found with:

• Combined oral contraceptives 1
• Levonorgestrel intrauterine systems 2
• Progestin-only pills 1
• Subdermal implants 1

This makes these alternatives particularly appropriate for women with meningioma history or concerns about meningioma risk.

Contextualizing the Absolute Risk

While the relative risk is significant, the absolute risk remains modest. The number needed to harm of 1,152 patients means that for every 1,152 women using DMPA, one additional case of meningioma would be expected beyond baseline rates 1. For comparison, the baseline incidence of meningioma in women aged 20-49 is approximately 7-10 per 100,000 person-years.

Special Populations

Adolescents and young women (<31 years): The risk appears lower in this age group, and DMPA remains a highly effective contraceptive option when other methods are unsuitable 8, 9. However, the 2014 Pediatrics guidelines predate the meningioma data and should be interpreted with this new evidence in mind.

Women with existing risk factors: Those with prior radiation exposure, neurofibromatosis type 2, or family history of meningioma warrant extra caution and consideration of alternative contraceptives.

Common Pitfalls to Avoid

1. Don't dismiss new headaches in long-term DMPA users as "just hormonal" - maintain clinical suspicion for meningioma
2. Don't continue DMPA indefinitely without periodic reassessment of risks versus benefits
3. Don't assume all progestins carry equal risk - levonorgestrel IUD and other contraceptive progestins show no association 2
4. Don't forget to document the meningioma risk discussion in the medical record for medicolegal protection